Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation
暂无分享,去创建一个
S Kako | H. Nakasone | Y. Tanaka | R. Yamazaki | K. Terasako | M. Sato | S. Kimura | A. Tanihara | S. Kako | J. Nishida | Y. Kanda | S Kimura | K Oshima | S Okuda | K Sato | M Sato | K Terasako | H Nakasone | R Yamazaki | Y Tanaka | A Tanihara | T Higuchi | J Nishida | Y Kanda | T. Higuchi | K. Oshima | S. Okuda | K. Sato
[1] B. Wolf,et al. Measurement of cyclosporine concentrations in whole blood: HPLC and radioimmunoassay with a specific monoclonal antibody and 3H- or 125I-labeled ligand compared. , 1989, Clinical chemistry.
[2] B. Carleton,et al. INTERACTION BETWEEN CYCLOSPORINE AND FLUCONAZOLE IN RENAL ALLOGRAFT RECIPIENTS , 1991, Transplantation.
[3] J. López-Gil,et al. Fluconazole-Cyclosporine Interaction: A Dose-Dependent Effect? , 1993, The Annals of pharmacotherapy.
[4] J. Kovarik,et al. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. , 1994, Transplantation proceedings.
[5] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[6] J. Wingard,et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. , 1996, Transplantation.
[7] A. Gratwohl,et al. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT) , 1997, Bone Marrow Transplantation.
[8] E. Milgalter,et al. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506). , 1997, Transplantation proceedings.
[9] D. Min,et al. Effect of Grapefruit Juice on the Pharmacokinetics of Microemulsion Cyclosporine and its Metabolite in Healthy Volunteers: Does the Formulation Difference Matter? , 1998, Journal of clinical pharmacology.
[10] J. Spence,et al. Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.
[11] H. Esperou,et al. New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients , 2000, Bone Marrow Transplantation.
[12] S. Mineishi,et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan , 2001, Bone Marrow Transplantation.
[13] D. Nicolau,et al. Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. , 2003, Transplantation proceedings.
[14] H. Leather. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know , 2004, Bone Marrow Transplantation.
[15] K. Oka,et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. , 2005, Transplantation proceedings.
[16] J. Wingard,et al. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] Y. Kanda,et al. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA‐matched sibling donor , 2006, American journal of hematology.
[18] R. Yamazaki,et al. Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole , 2007, European Journal of Clinical Pharmacology.
[19] H. Nakasone,et al. Decreased incidence of acute graft‐versus‐host disease by continuous infusion of cyclosporine with a higher target blood level , 2008, American journal of hematology.
[20] H. Nakasone,et al. Long‐term ultra‐low‐dose acyclovir against varicella‐zoster virus reactivation after allogeneic hematopoietic stem cell transplantation , 2007, American journal of hematology.
[21] Jun Kato,et al. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients , 2009, Bone Marrow Transplantation.
[22] H. Nakasone,et al. Fludarabine, cyclophosphamide, anti‐thymocyteglobulin, and low‐dose total body irradiation conditioning enables 1‐HLA‐locus‐mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function , 2009, American journal of hematology.